News

Yahoo Finance3mon
U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic ...
and Phase 1 pharmacokinetic study If approved, ZORYVE cream 0.05% will be a new topical therapy option for approximately 1.8 million children aged 2 to 5 with atopic dermatitis (AD) in the United ...
Medindia2mon
ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age
The approval of ZORYVE cream 0.15% for atopic dermatitis in Canada was supported by positive results from the vehicle-controlled pivotal Phase 3 INTEGUMENT-1 and INTEGUMENT-2 trials, in which ro?
Nasdaq22d
Arcutis Biotherapeutics Reports Positive Phase 3 Study Results for Investigational ZORYVE Foam 0.3% in Treating Scalp and Body Psoriasis
The most common adverse reactions (≥1%) for ZORYVE cream 0.3% for plaque psoriasis include diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%), application site pain (1.0%), upper ...
Healio2mon
Adults, children maintain mild AD during treatment-free period follow Vtama cream 1%
0.4% for contact dermatitis and 0% for headaches. Approved by the FDA in December 2024 for adults and pediatric patients aged as young as 2 years, Vtama cream 1% helps “simplify” patients ...
Yahoo Finance2mon
ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age
Atopic dermatitis, the most prevalent form of eczema, is a chronic and relapsing skin condition that usually presents early in life i. It is characterized by intensely itchy and inflamed skin, ...